Targeted therapies in the management of renal cell carcinoma: role of bevacizumab
Bernard Escudier1, Jan Cosaert2, Sangeeta Jethwa21Unité Immunothérapie, Institut Gustave Roussy, Villejuif, France; 2F. Hoffmann-La Roche Ltd, Basel, SwitzerlandAbstract: Bevacizumab (10 mg/kg every 2 weeks), in combination with interferon alpha-2a (IFN), is an effectiv...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2008-09-01
|
| Series: | Biologics : Targets & Therapy |
| Online Access: | http://www.dovepress.com/targeted-therapies-in-the-management-of-renal-cell-carcinoma-role-of-b-a2301 |